Comparative Pharmacology
Head-to-head clinical analysis: EC NAPROSYN versus INDICLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EC NAPROSYN versus INDICLOR.
EC-NAPROSYN vs INDICLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription.
500-1000 mg orally twice daily; maximum 1500 mg/day.
INDICLOR is not a recognized drug; no standard dosing available.
None Documented
None Documented
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
Terminal elimination half-life is 12 hours (range 10-15 hours) in patients with normal renal function; prolonged in renal impairment (up to 25 hours in severe cases).
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
Primarily renal excretion (approximately 70% unchanged drug); biliary/fecal excretion accounts for about 10-15% as metabolites.
Category C
Category C
NSAID
NSAID